Q3 Earnings Forecast for CGEM Issued By HC Wainwright

Cullinan Therapeutics, Inc. (NASDAQ:CGEM) – Equities research analysts at HC Wainwright issued their Q3 2025 EPS estimates for shares of Cullinan Therapeutics in a note issued to investors on Thursday, August 21st. HC Wainwright analyst R. Burns forecasts that the company will earn ($0.98) per share for the quarter. HC Wainwright has a “Buy” rating and a $24.00 price objective on the stock. The consensus estimate for Cullinan Therapeutics’ current full-year earnings is ($3.04) per share. HC Wainwright also issued estimates for Cullinan Therapeutics’ Q4 2025 earnings at ($1.02) EPS, FY2025 earnings at ($4.01) EPS, Q3 2026 earnings at ($1.12) EPS, Q4 2026 earnings at ($1.15) EPS and FY2026 earnings at ($4.40) EPS.

Several other brokerages also recently weighed in on CGEM. UBS Group reduced their price target on Cullinan Therapeutics from $30.00 to $24.00 and set a “buy” rating for the company in a report on Monday, May 12th. Morgan Stanley reduced their price target on Cullinan Therapeutics from $35.00 to $28.00 and set an “overweight” rating for the company in a research report on Monday, August 18th. Finally, Stifel Nicolaus initiated coverage on Cullinan Therapeutics in a research note on Wednesday, June 11th. They issued a “buy” rating and a $22.00 price target for the company. Five analysts have rated the stock with a Buy rating, According to MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $26.80.

Cullinan Therapeutics Trading Down 6.7%

CGEM opened at $7.64 on Monday. Cullinan Therapeutics has a 12-month low of $6.85 and a 12-month high of $19.89. The stock has a fifty day simple moving average of $7.77 and a two-hundred day simple moving average of $8.14. The company has a market cap of $451.29 million, a price-to-earnings ratio of -2.37 and a beta of -0.08.

Cullinan Therapeutics (NASDAQ:CGEM) last released its quarterly earnings results on Thursday, August 7th. The company reported ($1.07) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.83) by ($0.24).

Institutional Trading of Cullinan Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the business. Brooklyn Investment Group purchased a new stake in Cullinan Therapeutics in the first quarter valued at about $34,000. GAMMA Investing LLC raised its position in shares of Cullinan Therapeutics by 1,214.8% in the 1st quarter. GAMMA Investing LLC now owns 6,995 shares of the company’s stock valued at $53,000 after purchasing an additional 6,463 shares during the last quarter. Tower Research Capital LLC TRC raised its position in shares of Cullinan Therapeutics by 44.6% in the 2nd quarter. Tower Research Capital LLC TRC now owns 8,182 shares of the company’s stock valued at $62,000 after purchasing an additional 2,523 shares during the last quarter. Virtus ETF Advisers LLC raised its position in shares of Cullinan Therapeutics by 37.8% in the 4th quarter. Virtus ETF Advisers LLC now owns 5,828 shares of the company’s stock valued at $71,000 after purchasing an additional 1,600 shares during the last quarter. Finally, Aquatic Capital Management LLC purchased a new position in shares of Cullinan Therapeutics in the fourth quarter worth $77,000. Hedge funds and other institutional investors own 86.31% of the company’s stock.

Cullinan Therapeutics Company Profile

Cullinan Therapeutics, Inc, a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer.